Displaying drugs 12951 - 12975 of 14915 in total
Deoxynucleogene ancparvovec
Investigational
AML-2-23
Investigational
CypCaps
Investigational
DNP-Modified autologous tumor vaccine
Investigational
Myb34.5
Investigational
Albumin-stabilized nanoparticle (130 nm)
Investigational
Boserolimab
Investigational
CD8+ enriched young tumor infiltrating lymphocytes
Investigational
TASO-001
TASO-001 is a transforming growth factor (TGF)-beta 2 specific antisense oligodeoxynucleotide.
Investigational
CD-16 NK-92 cells
Investigational
LP-2307
LP-2307 is an investigational allogeneic large multivalent immunogen (LMI) vaccine developed by Avanir. It was investigated for melanoma.
Investigational
APL-502
APL 502 is a humanised immunoglobulin G1 (IgG1) monoclonal antibody targeting the programmed cell death-1 ligand-1 (PD-L1).
Investigational
Anselamimab
Investigational
Autogene cevumeran
Autogene cevumeran is an mRNA-based cancer vaccine targeting an unspecified amount of tumour-associated antigens. It is being investigated for cancers.
Investigational
Casdozokitug
Investigational
Batiraxcept
Investigational
ETBX-051
Investigational
GCS-100
Investigational
Crefmirlimab
Crefmirlimab is an anti-human CD8 probe targeting the CD8 antigen, for the diagnosis of various cancers.
Investigational
PEG-interleukin-2
Investigational
RP-L201
Investigational
OCE-205
Investigational
Clervonafusp alfa
Investigational
AEM-28
AEM-28 is a 28 amino acid mimetic of apolipoprotein E being investigated for lipid disorders, such as homozygous familial hypercholesterolemia. It possesses anti-inflammatory properties.
Investigational
Displaying drugs 12951 - 12975 of 14915 in total